Team:Wageningen UR

From 2012.igem.org

(Difference between revisions)
Line 44: Line 44:
<div class="col">
<div class="col">
-
<a href="https://2012.igem.org/Team:Wageningen_UR/TheConstructor" title="Project Description" class="bigbutton" style="background: #b92c33;">
 
-
<span>The Constructor. An application that assists you in creating your cloning strategies for your iGem project.</span>
 
-
</a>
 
-
<br /><br />
+
<h2 class="ulc3">The Constructor</h2>
 +
<p><a href="https://2012.igem.org/Team:Wageningen_UR/TheConstructor" title="The Constructor">An application that assists you in creating your cloning strategies for your iGem project.</a></p>
-
<a href="https://2012.igem.org/Team:Wageningen_UR/Team" title="Meet the Team" class="bigbutton"><img  src="http://www.the-falcons.nl/igem2/img/theteam.png" alt="The Project" /></a>
+
<br />
 +
 
 +
<h2 class="ulc1">The Team</h2>
 +
<p><a href="https://2012.igem.org/Team:Wageningen_UR/Team" title="Meet the Team">Meet the team!</a></p>
</div>
</div>

Revision as of 07:44, 11 September 2012

P'NAS

Coming soon...

VLPs' origins

Coming soon...

Outside modification

Coming soon...

Inside modification

Coming soon...

Applications

Coming soon...

Abstract

A standardized tool for site specific drug delivery using Virus-Like Particles

Medicines are generally active in a non-site-specific fashion, affecting the whole patient, including healthy tissue. Therefore, we attempt to specifically target diseased areas by packaging medicines inside Virus-Like Particles (VLPs). VLPs are not infectious, as they are built solely from viral coat proteins. We designed a modular Plug and Apply system that enables modifications to these coat proteins. The system facilitates the linkage of numerous ligands to the coat protein, thereby creating site-specific carriers. After expression of coat protein genes in Escherichia coli the VLPs were assembled in vitro, yielding modified Virus-Like Particles. Medicines can be packed using the Plug and Apply system or simply by addition during VLP assembly. Concluding, VLPs can be used as universal carriers for site-specific drug delivery, allowing customization to a variety of diseases while decreasing side effects for patients during treatment.

Social Stream